What's Happening?
Kerecis, a company specializing in fish-skin grafts for cellular therapy and tissue regeneration, is presenting new clinical data at the Symposium on Advanced Wound Care (SAWC) Spring 2026 in Charlotte, North Carolina. The data highlights the superior
effectiveness of intact fish-skin grafts over standard care for treating severe Stage 3 and 4 pressure ulcers. The symposium will feature presentations by clinicians and researchers, including Dr. John C. Lantis II, who will discuss the clinical applications of fish-skin grafts in chronic and atypical wounds. The trial demonstrated significant wound reduction and higher healing rates compared to standard care.
Why It's Important?
The presentation of new clinical data on fish-skin grafts is crucial as it provides real-world validation for the effectiveness of Kerecis' technology in treating complex wounds. This innovation represents a significant advancement in wound care, offering a sustainable and effective alternative to traditional treatments. The findings could lead to broader adoption of fish-skin grafts across various medical specialties, potentially improving patient outcomes and reducing healthcare costs associated with chronic wound management. The use of sustainably sourced fish-skin also aligns with environmental goals, promoting eco-friendly medical solutions.
